Systematic Review and Meta-Analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke: an Update.
Systematic Review and Meta-Analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke: an Update.
复制标题
DOI：
10.1007/s12975-016-0489-z
复制
发表时间：
2016-10
影响因子：
6.9
通讯作者：
Sena, Emily S.
中科院分区：
文献类型：
--
作者：
McCann, Sarah K.;Cramond, Fala;Macleod, Malcolm R.;Sena, Emily S.
关键词：
白细胞介素-1受体拮抗剂（IL-1 RA）是一种抗炎蛋白，临床上用于治疗类风湿关节炎，被认为是一种有前途的治疗中风的候选药物。在此，我们试图更新2009年发表的缺血性卒中模型中IL-1 RA的现有系统性综述和荟萃分析，以评估疗效、已检验疗效的情况范围以及数据是否因报告的研究质量和发表偏倚而出现混淆。我们纳入了25个数据来源，其中11个是原始综述的补充。总的来说，IL-1 RA使梗死体积减少36.2%（95%置信区间31.6-40.7，n = 76个比较，来自1283只动物）。发表偏倚评估表明，30项理论上缺失的研究将疗效降低至21.9%（17.3-26.4）。IL-1 RA直接给予心室而不是外周的疗效更高，并且在诱导缺血期间未报告分配隐藏的研究报告了更大的治疗效果。支持IL-1 RA作为缺血性卒中候选疗法的临床前数据已经得到改善。在本次更新中，降低偏倚风险的措施报告有了显著改善，研究现在包括使用具有相关共病的动物。本文的在线版本（doi：10.1007/s12975-016-0489-z）包含补充材料，可供授权用户使用。
Interleukin-1 receptor antagonist (IL-1 RA) is an anti-inflammatory protein used clinically to treat rheumatoid arthritis and is considered a promising candidate therapy for stroke. Here, we sought to update the existing systematic review and meta-analysis of IL-1 RA in models of ischaemic stroke, published in 2009, to assess efficacy, the range of circumstances in which efficacy has been tested and whether the data appear to be confounded due to reported study quality and publication bias. We included 25 sources of data, 11 of which were additional to the original review. Overall, IL-1 RA reduced infarct volume by 36.2 % (95 % confidence interval 31.6–40.7, n = 76 comparisons from 1283 animals). Assessments for publication bias suggest 30 theoretically missing studies which reduce efficacy to 21.9 % (17.3–26.4). Efficacy was higher where IL-1 RA was administered directly into the ventricles rather than peripherally, and studies not reporting allocation concealment during the induction of ischaemia reported larger treatment effects. The preclinical data supporting IL-1 RA as a candidate therapy for ischaemic stroke have improved. The reporting of measures to reduce the risk of bias has improved substantially in this update, and studies now include the use of animals with relevant co-morbidities. The online version of this article (doi:10.1007/s12975-016-0489-z) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
10.4
作者：
Krauth D;Woodruff TJ;Bero L
通讯作者：
Bero L
DOI：
10.1097/01.wcb.0000048519.34839.97
发表时间：
2003-03-01
影响因子：
6.3
作者：
Le Feuvre, RA;Brough, D;Rothwell, NJ
通讯作者：
Rothwell, NJ
影响因子：
2.4
作者：
Hooijmans CR;Tillema A;Leenaars M;Ritskes-Hoitinga M
通讯作者：
Ritskes-Hoitinga M
影响因子：
2.7
作者：
Girard, Sylvie;Murray, Katie N.;Rothwell, Nancy J.;Metz, Gerlinde A. S.;Allan, Stuart M.
通讯作者：
Allan, Stuart M.
影响因子：
5.3
作者：
McColl, Barry W.;Rothwell, Nancy J.;Allan, Stuart M.
通讯作者：
Allan, Stuart M.